Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain data for Arcturus’ lyophilized vaccine platform shows favorable stability, shipping, and storage advantages European Commission grants Orphan Medicinal Product Designation to ARCT-810, a novel mRNA candidate for ornithine … [Read more…]
